Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | SELE | P16581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8284426 | 0.79 | GRM5 (0.37) | KDM4CGRM5RORCMEN1KMT2A | |
| SCHEMBL80199 | 0.78 | KDM4C (0.38) | KDM4CGRM5RORCMEN1KMT2A | |
| SCHEMBL14459299 | 0.76 | GCK (0.37) | KDM4CGRM5RORCMEN1KMT2A | |
| SCHEMBL14476044 | 0.76 | KDM4C (0.43) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL18465036 | 0.75 | GRM5 (0.39) | KDM4CGRM5RORCMEN1KMT2A | |
| SCHEMBL5990774 | 0.74 | GRM5 (0.44) | KDM4CGRM5RORCMEN1KMT2A | |
| SCHEMBL31419836 | 0.72 | HTR2A (0.45) | KDM4CGRM5RORCMEN1KMT2A | |
| SCHEMBL30740345 | 0.72 | GRM5 (0.46) | KDM4CGRM5RORCMEN1KMT2A | |
| SCHEMBL18196418 | 0.71 | KDM4C (0.39) | KDM4CGRM5RORCMEN1KMT2A | |
| SCHEMBL18188279 | 0.71 | KDM4C (0.39) | KDM4CGRM5RORCMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1232150-B1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1232150-B1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7241758-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241758-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-6765009-B2 | N-(5-TERT-BUTYL-3-(3-(4-((2-DIMETHYLAMINOMETHYL-PYRIDIN-4-YL) -PIPERAZIN-1-YL-METHYL) NAPHTHALEN-1-YL)UREIDO)-2-METHOXYPHENYL) METHANESULFONAMIDE FOR EXAMPLE; CYTOKINE INHIBITORS FOR TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-07-20 | — | — | US | disclosed |
| EP-1381592-A1 | 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030125354-A1 | Compounds use as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | BOEHRINGER INTELHEIM PHARMACEUTICALS, INC. | 2003-05-01 | — | — | US | disclosed |
| US-6492393-B1 | SUCH AS 1-(5-TERT-BUTYL-2-METHOXYPHENYL)-3-(4-(2-METHOXY-PYRIDIN-4YL-OXY)-NAPHTHALEN-1-YL)-UREA; CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| WO-2002083628-A1 | 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1232150-A1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001036403-A1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125354-A1 | Compounds use as anti-inflammatory agents | EPX, MPO, RELA | KDM4C 2842/4885GRM5 610/4885RORC 18/4885 |
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | RELA, NFKBIA, NQO1 | KDM4C 1160/4885GRM5 831/4885RORC 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.